Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 (...) ) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses
in patients with HER2-positive advanced gastric cancer. Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab, were randomly assigned in a 2:1 ratio to receive trastuzumab deruxtecan (6.4 mg per kilogram of body weight every 3 weeks) or physician's choice of chemotherapy. The primary end point was the objective response, according to independent central review (...) trastuzumab deruxtecan-related interstitial lung disease or pneumonitis (grade 1 or 2 in 9 patients and grade 3 or 4 in 3), as adjudicated by an independent committee. One drug-related death (due to pneumonia) was noted in the trastuzumab deruxtecan group; no drug-related deaths occurred in the physician's choice group.Therapy with trastuzumab deruxtecan led to significant improvements in response and overall survival, as compared with standard therapies, among patients with HER2-positive gastric cancer
H pylori treatment reduced risk for gastric cancer in patients with a family history of gastric cancer. Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer andHelicobacter pyloritreatment. N Engl J Med. 2020;382:427-36. 31995688.
Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled (...) into a randomised trial of daily aspirin versus placebo. This report completes the planned 10-year follow-up to allow a longer-term assessment of the effect of taking regular aspirin in this high-risk population.In the double-blind, randomised CAPP2 trial, 861 patients from 43 international centres worldwide (707 [82%] from Europe, 112 [13%] from Australasia, 38 [4%] from Africa, and four [<1%] from The Americas) with Lynch syndrome were randomly assigned to receive 600 mg aspirin daily or placebo. Cancer
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. Injectable luteinizing hormone-releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of leuprolide are not known.In this phase 3 trial, we randomly assigned patients (...) with advanced prostate cancer, in a 2:1 ratio, to receive relugolix (120 mg orally once daily) or leuprolide (injections every 3 months) for 48 weeks. The primary end point was sustained testosterone suppression to castrate levels (<50 ng per deciliter) through 48 weeks. Secondary end points included noninferiority with respect to the primary end point, castrate levels of testosterone on day 4, and profound castrate levels (<20 ng per deciliter) on day 15. Testosterone recovery was evaluated in a subgroup
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy. Results from the final analysis of overall survival have not yet been reported.In this double-blind, phase 3 trial, men with nonmetastatic (...) , castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months) who were continuing to receive androgen-deprivation therapy were randomly assigned (in a 2:1 ratio) to receive enzalutamide at a dose of 160 mg or placebo once daily. Overall survival was assessed with a group sequential testing procedure and an O'Brien-Fleming-type alpha-spending function.As of October 15, 2019, a total of 288 of 933 patients (31%) in the enzalutamide group and 178
of liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). Recent data confirm that HCC represents the fifth most common cancer and is the second leading cause of cancer-related death worldwide, and NAFLD has been identified as a rapidly emerging risk factor for this malignancy. NAFLD-associated liver complications are projected to become the leading indication for liver transplantation in the next decade. Despite evidence that NAFLD-associated HCC may arise in the absence (...) Carcinoma Screening Several studies have shown that patients with NAFLD without cirrhosis may, albeit rarely, develop HCC. Stine J.G. Wentworth B.J. Zimmet A. et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018; 48 : 696-703 White et al White D.L. Kanwal F. El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based
background data: Numerous studies have compared both strategies. All were retrospective and conclusions were contradictory. Methods: Adults with colorectal cancer and resectable SLM were randomly assigned to either simultaneous or delayed resection of the metastases. The primary outcome was the rate of major complications within 60 days following surgery. Secondary outcomes included overall and disease-free survival. Results: A total of 105 patients were recruited. Eighty-five patients (39 and 46 (...) group, 8 patients did not reach the liver resection stage, and this was due to disease progression in 6 cases. After 2 years, overall and disease-free survival tended to be improved in simultaneous as compared with delayed-resection groups (P = 0.05), a tendency which persisted for OS after a median follow-up of 47 months. Conclusions: Complication rates did not appear to differ when colorectal cancer and synchronous liver metastases are resected simultaneously. Delayed resection tended to impair
of interest). The scope is limited to curative management of invasive carcinomas of the uterine cervix, which include squamous cell carcinomas and adenocarcinomas, and does not include rare histologies, noninvasive disease or palliative treatment. It focuses on management of cervical cancer with RT and its indications, techniques, and outcomes. It additionally covers other therapies that modify the efficacy of RT when used concurrently or in sequence (eg, chemotherapy or surgery). Key Questions (...) no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999; 73 : 177-183 Occult cervical cancer after total hysterectomy For women who are found to have an occult invasive cervical cancer after total hysterectomy (either for benign disease or uterine cancer), further treatment is needed for stages greater than or equal to IA2 because a radical hysterectomy with lymph node
Management of Cancer Cachexia Supportive Care and Treatment Related Issues | ASCO Search form Search ASCO Family of Sites ASCOconnection.org features blogs from members, the online version of the membership magazine, a discussion area, working groups, and links to the Membership Directory, Career Center, and Volunteer Portal. ASCO Daily News is the official conference reporter for ASCO meetings and symposia, providing high-quality, unbiased research summaries and oncology news to members (...) and oncology health care providers. ASCO’s growing roster of cutting-edge journals serves readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe. ASCO Practice Central helps oncology professionals navigate a complicated and ever-changing practice environment—while providing high-quality patient care. ASCO eLearning serves as a comprehensive online learning
of liver tumours, including radiofrequency, microwave and cryoablation techniques. This is a preview of subscription content, to check access. Access options References 1. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom, Charboneau JW, et al. International Working Group on Image-Guided Tumor Ablation, Interventional Oncology Sans Frontières Expert Panel, Technology Assessment Committee of the Society of Interventional Radiology, Standard of Practice Committee of the Cardiovascular and Interventional (...) Radiological Society of Europe, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. J Vasc Interv Radiol. 2014;25(11):1691–705. 2. Wang X, Sofocleous CT, Erinjeri JP, Petre EN, Gonen M, Do KG, et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Interv Radiol. 2013;36(1):166–75. 3. Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin
requiring further investigation and management. Addressing co-morbidities including obesity-related issues, hypertension and diabetes is important with evidence suggesting that, overall, cardiovascular disease is the leading cause of death among endometrial cancer patients. 3 Interventions and investigations aimed at addressing risk factors for these diseases may have the greatest potential to improve outcomes for women diagnosed with low-risk endometrial cancer. GPs can provide whole person care (...) below. Identify, monitor and manage newly emerging or ongoing co-morbidities as required, including obesity, diabetes and cardiovascular disease Actively promote secondary prevention strategies and encourage realistic goal-setting (including maintaining a healthy body weight, regular exercise, quitting smoking and limiting alcohol intake) Women who require management of menopausal symptoms after treatment of endometrial cancer should be managed in consultation with the treating gynaecological cancer
, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 6 N N Petrov Research Institute of Oncology, St Petersburg, Russia. 7 12 de Octubre University Hospital, Medical Oncology Department, Madrid, Spain. 8 National Center for TumorDiseases, University Hospital, German Cancer Research Center, Heidelberg, Germany. 9 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 10 F Hoffmann-La Roche, Basel, Switzerland. 11 Roche Products, Welwyn Garden City, UK. 12 (...) , Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 6 N N Petrov Research Institute of Oncology, St Petersburg, Russia. 7 12 de Octubre University Hospital, Medical Oncology Department, Madrid, Spain. 8 National Center for TumorDiseases, University Hospital, German Cancer Research Center, Heidelberg, Germany. 9 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 10 F Hoffmann-La Roche, Basel, Switzerland. 11 Roche Products, Welwyn Garden City, UK. 12
survival (rPFS) versus ADT alone. Objective: To evaluate patient-reported outcomes (PROs) to week 73. Design, setting, and participants: ARCHES ( ) was a randomised, double-blind, placebo-controlled, phase 3 study in mHSPC patients. Intervention: Enzalutamide (160 mg/day) plus ADT or placebo plus ADT. Outcome measurements and statistical analysis: PROs were assessed at baseline, week 13, and every 12 wk until disease progression using the European Organisation for Research and Treatment of Cancer (...) for confirmed deterioration for pain outcomes). Enzalutamide delays deterioration in several HRQoL subscales and pain severity in high-volume disease. Conclusions: Enzalutamide plus ADT enables men with mHSPC to maintain high-functioning HRQoL and low symptom burden. Patient summary: This study examined the effect on health-related quality of life and pain of adding enzalutamide or placebo to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer. Addition